Literature DB >> 25483429

In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model.

Joana M Silva1, Eva Zupancic2, Gaëlle Vandermeulen3, Vanessa G Oliveira4, Ana Salgado2, Mafalda Videira2, Manuela Gaspar2, Luis Graca4, Véronique Préat5, Helena F Florindo6.   

Abstract

We hypothesized that the co-entrapment of melanoma-associated antigens and the Toll-like receptor (TLR) ligands Poly(I:C) and CpG, known to be Th1-immunopotentiators, in mannose-functionalized aliphatic polyester-based nanoparticles (NPs) could be targeted to mannose receptors on antigen-presenting cells and induce anti-tumor immune responses. High entrapment efficiencies of antigens and immunopotentiators in 150nm NPs were obtained. The co-entrapment of the model antigen ovalbumin and the TLR ligands was crucial to induce high IgG2c/IgG1 ratios and high levels of IFN-γ and IL-2. Mannose-functionalization of NPs potentiated the Th1 immune response. The nanoparticulate vaccines decreased the growth rate of murine B16F10 melanoma tumors in therapeutic and prophylatic settings. The combination of mannose-functionalized NPs containing MHC class I- or class II-restricted melanoma antigens and the TLR ligands induced the highest tumor growth delay. Overall, we demonstrate that the multifunctional properties of NPs in terms of targeting and antigen/adjuvant delivery have high cancer immunotherapeutic potential.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antigen presenting cells; Cancer vaccine; Mannose receptor targeting; Melanoma; Nanoparticles; PLGA; TLR

Mesh:

Substances:

Year:  2014        PMID: 25483429     DOI: 10.1016/j.jconrel.2014.11.033

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  31 in total

1.  Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.

Authors:  Sean M Geary; Qiaohong Hu; Vijaya B Joshi; Ned B Bowden; Aliasger K Salem
Journal:  J Control Release       Date:  2015-09-08       Impact factor: 9.776

2.  Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines.

Authors:  Laure Lambricht; Kevin Vanvarenberg; Ans De Beuckelaer; Lien Van Hoecke; Johan Grooten; Bernard Ucakar; Pascale Lipnik; Niek N Sanders; Stefan Lienenklaus; Véronique Préat; Gaëlle Vandermeulen
Journal:  Mol Ther       Date:  2016-06-20       Impact factor: 11.454

Review 3.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Genome-wide transcriptional analysis of silica nanoparticle-induced toxicity in zebrafish embryos.

Authors:  Hejing Hu; Qiuling Li; Lizhen Jiang; Yang Zou; Junchao Duan; Zhiwei Sun
Journal:  Toxicol Res (Camb)       Date:  2016-01-20       Impact factor: 3.524

5.  α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.

Authors:  Vanessa Sainz; Liane I F Moura; Carina Peres; Ana I Matos; Ana S Viana; Angela M Wagner; Julia E Vela Ramirez; Teresa S Barata; Manuela Gaspar; Steve Brocchini; Mire Zloh; Nicholas A Peppas; Ronit Satchi-Fainaro; Helena F Florindo
Journal:  Acta Biomater       Date:  2018-06-22       Impact factor: 8.947

Review 6.  Biomimetic Nanotechnology toward Personalized Vaccines.

Authors:  Jiarong Zhou; Ashley V Kroll; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Mater       Date:  2019-06-17       Impact factor: 30.849

Review 7.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

Review 8.  Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.

Authors:  Katharina Maisel; Maria Stella Sasso; Lambert Potin; Melody A Swartz
Journal:  Adv Drug Deliv Rev       Date:  2017-07-08       Impact factor: 15.470

9.  Biomimetic Nanoparticle Vaccines for Cancer Therapy.

Authors:  Ashley V Kroll; Yao Jiang; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Biosyst       Date:  2018-11-13

10.  Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.

Authors:  Michael A Collier; Robert D Junkins; Matthew D Gallovic; Brandon M Johnson; Monica M Johnson; Andrew N Macintyre; Gregory D Sempowski; Eric M Bachelder; Jenny P-Y Ting; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2018-10-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.